AMAG Pharmaceuticals, Inc. (AMAG)
(Delayed Data from NSDQ)
$11.57 USD
+0.34 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.57 USD
+0.34 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Palatin (PTN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.
AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG (AMAG) to be Acquired by Covis Group for $647 Million
by Zacks Equity Research
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
AMAG Pharmaceuticals (AMAG) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
by Zacks Equity Research
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is AMAG Pharmaceuticals (AMAG) Up 6.8% Since Last Earnings Report?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG Pharmaceuticals (AMAG) Down 21.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
by Zacks Equity Research
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -2.94% and 1.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Proteostasis (PTI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.
Is a Surprise Coming for AMAG This Earnings Season?
by Zacks Equity Research
AMAG is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
What in Store for Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.
Teladoc (TDOC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q4 performance is likely to have benefited from increased membership and visits.